Eintrag weiter verarbeiten
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004
Gespeichert in:
| Zeitschriftentitel: | Clinical Cancer Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | Clinical Cancer Research, 19, 2013, 7, S. 1884-1893 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Somlo, George Atzori, Francesco Strauss, Lewis C. Geese, William J. Specht, Jennifer M. Gradishar, William J. Rybicki, Alissa Sy, Oumar Vahdat, Linda T. Cortes, Javier Somlo, George Atzori, Francesco Strauss, Lewis C. Geese, William J. Specht, Jennifer M. Gradishar, William J. Rybicki, Alissa Sy, Oumar Vahdat, Linda T. Cortes, Javier |
|---|---|
| author |
Somlo, George Atzori, Francesco Strauss, Lewis C. Geese, William J. Specht, Jennifer M. Gradishar, William J. Rybicki, Alissa Sy, Oumar Vahdat, Linda T. Cortes, Javier |
| spellingShingle |
Somlo, George Atzori, Francesco Strauss, Lewis C. Geese, William J. Specht, Jennifer M. Gradishar, William J. Rybicki, Alissa Sy, Oumar Vahdat, Linda T. Cortes, Javier Clinical Cancer Research Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 Cancer Research Oncology |
| author_sort |
somlo, george |
| spelling |
Somlo, George Atzori, Francesco Strauss, Lewis C. Geese, William J. Specht, Jennifer M. Gradishar, William J. Rybicki, Alissa Sy, Oumar Vahdat, Linda T. Cortes, Javier 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-12-0652 <jats:title>Abstract</jats:title><jats:p>Purpose: Dasatinib is an Src family kinase inhibitor with modest activity in advanced breast cancer. We aimed to assess toxicity and maximum tolerated dose (MTD) for dasatinib plus capecitabine, estimate efficacy, and explore effects on angiogenesis.</jats:p><jats:p>Experimental Design: Dose levels (DL) were dasatinib 50 mg twice daily (DL1), 70 mg twice daily (DL2 and DL3), or 100 mg daily (DL3a); plus capecitabine on days 1 to 14 of a 21-day cycle, at 825 mg/m2 twice daily (DL1 and DL2) or 1,000 mg/m2 twice daily [DL3 and DL3a (MTD)]. DL3a was expanded to evaluate safety/efficacy. Plasma samples were collected for biomarker analysis.</jats:p><jats:p>Results: Thirty-one and 21 patients were treated in the escalation and expansion phases. Sixty percent of tumors were hormone receptor–positive. Most common adverse events (AE) were any grade nausea (58%), hand–foot syndrome (44%), diarrhea (33%), fatigue (33%), vomiting (31%), and asthenia (31%). Most common grade 3/4 AEs were hand–foot syndrome (12%), diarrhea (8%), fatigue (8%), pleural effusion (8%), and vomiting (6%). The MTD was defined at DL3a (capecitabine 1,000 mg/m2 twice daily and dasatinib 100 mg daily). Of 25 response-evaluable patients treated at DL3a, confirmed partial response was noted in 24% and stable disease in an additional 32%; median progression-free survival was 14.4 weeks. Significant decreases in plasma VEGF-A and increases in VEGFR-2 and collagen-IV were observed.</jats:p><jats:p>Conclusions: Dasatinib 100 mg once daily plus capecitabine 1,000 mg/m2 twice daily were tolerable and were associated with clinical benefit in 56% of response-evaluable patients. Biomarker changes were consistent with an antiangiogenic effect. Clin Cancer Res; 19(7); 1884–93. ©2013 AACR.</jats:p> Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 Clinical Cancer Research |
| doi_str_mv |
10.1158/1078-0432.ccr-12-0652 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTEyLTA2NTI |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTEyLTA2NTI |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Association for Cancer Research (AACR), 2013 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2013 |
| issn |
1078-0432 1557-3265 |
| issn_str_mv |
1078-0432 1557-3265 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
somlo2013dasatinibpluscapecitabineforadvancedbreastcancersafetyandefficacyinphaseistudyca180004 |
| publishDateSort |
2013 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Clinical Cancer Research |
| source_id |
49 |
| title |
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| title_unstemmed |
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| title_full |
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| title_fullStr |
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| title_full_unstemmed |
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| title_short |
Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| title_sort |
dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase i study ca180004 |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1078-0432.ccr-12-0652 |
| publishDate |
2013 |
| physical |
1884-1893 |
| description |
<jats:title>Abstract</jats:title><jats:p>Purpose: Dasatinib is an Src family kinase inhibitor with modest activity in advanced breast cancer. We aimed to assess toxicity and maximum tolerated dose (MTD) for dasatinib plus capecitabine, estimate efficacy, and explore effects on angiogenesis.</jats:p><jats:p>Experimental Design: Dose levels (DL) were dasatinib 50 mg twice daily (DL1), 70 mg twice daily (DL2 and DL3), or 100 mg daily (DL3a); plus capecitabine on days 1 to 14 of a 21-day cycle, at 825 mg/m2 twice daily (DL1 and DL2) or 1,000 mg/m2 twice daily [DL3 and DL3a (MTD)]. DL3a was expanded to evaluate safety/efficacy. Plasma samples were collected for biomarker analysis.</jats:p><jats:p>Results: Thirty-one and 21 patients were treated in the escalation and expansion phases. Sixty percent of tumors were hormone receptor–positive. Most common adverse events (AE) were any grade nausea (58%), hand–foot syndrome (44%), diarrhea (33%), fatigue (33%), vomiting (31%), and asthenia (31%). Most common grade 3/4 AEs were hand–foot syndrome (12%), diarrhea (8%), fatigue (8%), pleural effusion (8%), and vomiting (6%). The MTD was defined at DL3a (capecitabine 1,000 mg/m2 twice daily and dasatinib 100 mg daily). Of 25 response-evaluable patients treated at DL3a, confirmed partial response was noted in 24% and stable disease in an additional 32%; median progression-free survival was 14.4 weeks. Significant decreases in plasma VEGF-A and increases in VEGFR-2 and collagen-IV were observed.</jats:p><jats:p>Conclusions: Dasatinib 100 mg once daily plus capecitabine 1,000 mg/m2 twice daily were tolerable and were associated with clinical benefit in 56% of response-evaluable patients. Biomarker changes were consistent with an antiangiogenic effect. Clin Cancer Res; 19(7); 1884–93. ©2013 AACR.</jats:p> |
| container_issue |
7 |
| container_start_page |
1884 |
| container_title |
Clinical Cancer Research |
| container_volume |
19 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792348010296901633 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T18:04:22.972Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Dasatinib+plus+Capecitabine+for+Advanced+Breast+Cancer%3A+Safety+and+Efficacy+in+Phase+I+Study+CA180004&rft.date=2013-04-01&genre=article&issn=1557-3265&volume=19&issue=7&spage=1884&epage=1893&pages=1884-1893&jtitle=Clinical+Cancer+Research&atitle=Dasatinib+plus+Capecitabine+for+Advanced+Breast+Cancer%3A+Safety+and+Efficacy+in+Phase+I+Study+CA180004&aulast=Cortes&aufirst=Javier&rft_id=info%3Adoi%2F10.1158%2F1078-0432.ccr-12-0652&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792348010296901633 |
| author | Somlo, George, Atzori, Francesco, Strauss, Lewis C., Geese, William J., Specht, Jennifer M., Gradishar, William J., Rybicki, Alissa, Sy, Oumar, Vahdat, Linda T., Cortes, Javier |
| author_facet | Somlo, George, Atzori, Francesco, Strauss, Lewis C., Geese, William J., Specht, Jennifer M., Gradishar, William J., Rybicki, Alissa, Sy, Oumar, Vahdat, Linda T., Cortes, Javier, Somlo, George, Atzori, Francesco, Strauss, Lewis C., Geese, William J., Specht, Jennifer M., Gradishar, William J., Rybicki, Alissa, Sy, Oumar, Vahdat, Linda T., Cortes, Javier |
| author_sort | somlo, george |
| container_issue | 7 |
| container_start_page | 1884 |
| container_title | Clinical Cancer Research |
| container_volume | 19 |
| description | <jats:title>Abstract</jats:title><jats:p>Purpose: Dasatinib is an Src family kinase inhibitor with modest activity in advanced breast cancer. We aimed to assess toxicity and maximum tolerated dose (MTD) for dasatinib plus capecitabine, estimate efficacy, and explore effects on angiogenesis.</jats:p><jats:p>Experimental Design: Dose levels (DL) were dasatinib 50 mg twice daily (DL1), 70 mg twice daily (DL2 and DL3), or 100 mg daily (DL3a); plus capecitabine on days 1 to 14 of a 21-day cycle, at 825 mg/m2 twice daily (DL1 and DL2) or 1,000 mg/m2 twice daily [DL3 and DL3a (MTD)]. DL3a was expanded to evaluate safety/efficacy. Plasma samples were collected for biomarker analysis.</jats:p><jats:p>Results: Thirty-one and 21 patients were treated in the escalation and expansion phases. Sixty percent of tumors were hormone receptor–positive. Most common adverse events (AE) were any grade nausea (58%), hand–foot syndrome (44%), diarrhea (33%), fatigue (33%), vomiting (31%), and asthenia (31%). Most common grade 3/4 AEs were hand–foot syndrome (12%), diarrhea (8%), fatigue (8%), pleural effusion (8%), and vomiting (6%). The MTD was defined at DL3a (capecitabine 1,000 mg/m2 twice daily and dasatinib 100 mg daily). Of 25 response-evaluable patients treated at DL3a, confirmed partial response was noted in 24% and stable disease in an additional 32%; median progression-free survival was 14.4 weeks. Significant decreases in plasma VEGF-A and increases in VEGFR-2 and collagen-IV were observed.</jats:p><jats:p>Conclusions: Dasatinib 100 mg once daily plus capecitabine 1,000 mg/m2 twice daily were tolerable and were associated with clinical benefit in 56% of response-evaluable patients. Biomarker changes were consistent with an antiangiogenic effect. Clin Cancer Res; 19(7); 1884–93. ©2013 AACR.</jats:p> |
| doi_str_mv | 10.1158/1078-0432.ccr-12-0652 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xMDc4LTA0MzIuY2NyLTEyLTA2NTI |
| imprint | American Association for Cancer Research (AACR), 2013 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2013 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 1078-0432, 1557-3265 |
| issn_str_mv | 1078-0432, 1557-3265 |
| language | English |
| last_indexed | 2024-03-01T18:04:22.972Z |
| match_str | somlo2013dasatinibpluscapecitabineforadvancedbreastcancersafetyandefficacyinphaseistudyca180004 |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | 1884-1893 |
| publishDate | 2013 |
| publishDateSort | 2013 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Clinical Cancer Research |
| source_id | 49 |
| spelling | Somlo, George Atzori, Francesco Strauss, Lewis C. Geese, William J. Specht, Jennifer M. Gradishar, William J. Rybicki, Alissa Sy, Oumar Vahdat, Linda T. Cortes, Javier 1078-0432 1557-3265 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1078-0432.ccr-12-0652 <jats:title>Abstract</jats:title><jats:p>Purpose: Dasatinib is an Src family kinase inhibitor with modest activity in advanced breast cancer. We aimed to assess toxicity and maximum tolerated dose (MTD) for dasatinib plus capecitabine, estimate efficacy, and explore effects on angiogenesis.</jats:p><jats:p>Experimental Design: Dose levels (DL) were dasatinib 50 mg twice daily (DL1), 70 mg twice daily (DL2 and DL3), or 100 mg daily (DL3a); plus capecitabine on days 1 to 14 of a 21-day cycle, at 825 mg/m2 twice daily (DL1 and DL2) or 1,000 mg/m2 twice daily [DL3 and DL3a (MTD)]. DL3a was expanded to evaluate safety/efficacy. Plasma samples were collected for biomarker analysis.</jats:p><jats:p>Results: Thirty-one and 21 patients were treated in the escalation and expansion phases. Sixty percent of tumors were hormone receptor–positive. Most common adverse events (AE) were any grade nausea (58%), hand–foot syndrome (44%), diarrhea (33%), fatigue (33%), vomiting (31%), and asthenia (31%). Most common grade 3/4 AEs were hand–foot syndrome (12%), diarrhea (8%), fatigue (8%), pleural effusion (8%), and vomiting (6%). The MTD was defined at DL3a (capecitabine 1,000 mg/m2 twice daily and dasatinib 100 mg daily). Of 25 response-evaluable patients treated at DL3a, confirmed partial response was noted in 24% and stable disease in an additional 32%; median progression-free survival was 14.4 weeks. Significant decreases in plasma VEGF-A and increases in VEGFR-2 and collagen-IV were observed.</jats:p><jats:p>Conclusions: Dasatinib 100 mg once daily plus capecitabine 1,000 mg/m2 twice daily were tolerable and were associated with clinical benefit in 56% of response-evaluable patients. Biomarker changes were consistent with an antiangiogenic effect. Clin Cancer Res; 19(7); 1884–93. ©2013 AACR.</jats:p> Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 Clinical Cancer Research |
| spellingShingle | Somlo, George, Atzori, Francesco, Strauss, Lewis C., Geese, William J., Specht, Jennifer M., Gradishar, William J., Rybicki, Alissa, Sy, Oumar, Vahdat, Linda T., Cortes, Javier, Clinical Cancer Research, Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004, Cancer Research, Oncology |
| title | Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| title_full | Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| title_fullStr | Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| title_full_unstemmed | Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| title_short | Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| title_sort | dasatinib plus capecitabine for advanced breast cancer: safety and efficacy in phase i study ca180004 |
| title_unstemmed | Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004 |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1078-0432.ccr-12-0652 |